Samia Hamza1, Vanessa Cottet1, Nassime Touillon2, Vincent Dancourt3, Claire Bonithon-Kopp4, Côme Lepage1, Jean Faivre5. 1. Burgundy Digestive Cancer Registry, INSERM UMR 866, University of Burgundy, Dijon, France; University Hospital, Dijon, France. 2. Saône et Loire Cancer Screening Coordinating Centre, Charnay-Les-Mâcon, France. 3. Burgundy Digestive Cancer Registry, INSERM UMR 866, University of Burgundy, Dijon, France; Côte d'Or Cancer Screening Coordinating Centre, Dijon, France. 4. Burgundy Digestive Cancer Registry, INSERM UMR 866, University of Burgundy, Dijon, France; University Hospital, Dijon, France; Clinical Investigation Center-Clinical Epidemiology, INSERM CIC 1432, University Hospital, France. 5. Burgundy Digestive Cancer Registry, INSERM UMR 866, University of Burgundy, Dijon, France; University Hospital, Dijon, France. Electronic address: jean.faivre@u-bourgogne.fr.
Abstract
BACKGROUND: Several randomized trials have shown a reduction of colorectal cancer mortality by screening using guaiac-based faecal occult blood tests. However, little is known on the long-term effect of screening at the population level in everyday practice. METHODS: Small-sized geographic areas including a total of 91,199 individuals were allocated to either biennal screening using the Hemoccult-II test or no screening. The expected mortality and incidence in the cohort invited to screening was determined using mortality and incidence in the non-screened population. RESULTS: Colorectal cancer mortality was significantly lower in the population invited to screening than in the non-screened population after 11 screening rounds (standardized mortality ratio: 0.87; 0.80-0.94). The standardized mortality ratio remained significant whatever the duration of follow-up. This reduction in colorectal cancer mortality was more pronounced in those who participated in the first screening campaign, who were regular participants in screening rounds (standardized mortality ratio: 0.67; 0.59-0.76). In contrast, colorectal cancer incidence was not different between the screened and non-screened populations (standardized incidence ratio: 1.01; 0.96-1.06). CONCLUSION: Our findings confirm, in the long term, that screening with Hemoccult can reduce colorectal cancer mortality. The data also highlight the benefit of regular participation in screening and the absence of effect of screening on colorectal cancer incidence.
BACKGROUND: Several randomized trials have shown a reduction of colorectal cancer mortality by screening using guaiac-based faecal occult blood tests. However, little is known on the long-term effect of screening at the population level in everyday practice. METHODS: Small-sized geographic areas including a total of 91,199 individuals were allocated to either biennal screening using the Hemoccult-II test or no screening. The expected mortality and incidence in the cohort invited to screening was determined using mortality and incidence in the non-screened population. RESULTS:Colorectal cancer mortality was significantly lower in the population invited to screening than in the non-screened population after 11 screening rounds (standardized mortality ratio: 0.87; 0.80-0.94). The standardized mortality ratio remained significant whatever the duration of follow-up. This reduction in colorectal cancer mortality was more pronounced in those who participated in the first screening campaign, who were regular participants in screening rounds (standardized mortality ratio: 0.67; 0.59-0.76). In contrast, colorectal cancer incidence was not different between the screened and non-screened populations (standardized incidence ratio: 1.01; 0.96-1.06). CONCLUSION: Our findings confirm, in the long term, that screening with Hemoccult can reduce colorectal cancer mortality. The data also highlight the benefit of regular participation in screening and the absence of effect of screening on colorectal cancer incidence.
Authors: Yamile Molina; Katherine J Briant; Janeth I Sanchez; Mary A O'Connell; Beti Thompson Journal: Ethn Health Date: 2017-01-24 Impact factor: 2.772
Authors: Lucinda Bertels; Peter Lucassen; Kristel van Asselt; Evelien Dekker; Henk van Weert; Bart Knottnerus Journal: Scand J Prim Health Care Date: 2020-11-13 Impact factor: 2.581
Authors: Beverly B Green; Melissa L Anderson; Andrea J Cook; Jessica Chubak; Sharon Fuller; Richard T Meenan; Sally W Vernon Journal: J Gen Intern Med Date: 2021-05-28 Impact factor: 6.473